Magenta Therapeutics, Inc. is a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients with autoimmune diseases, blood cancers and genetic diseases. To harness the curative power of immune reset through stem cell transplant for more patients, Magenta has created a new stem cell biology discovery platform and is developing a comprehensive portfolio of novel therapeutics. The Company’s conditioning programs, including MGTA-117, its most advanced conditioning program, are designed to selectively remove disease-causing stem and/or immune cells from a patient prior to transplant, and to be far less toxic than the decades-old radiation and chemotherapy-based approaches, which are still the only available options. Within the Company’s mobilization program, MGTA-145 is its first-line stem cell mobilization product candidate, and it is designed to enable physicians to more easily collect a greater number of functional blood stem cells, known as hematopoietic stem cells or HSCs, from patients and donors to improve patient outcomes and scale the capacity of transplant and apheresis centers. MGTA-456 is a cell therapy designed to provide a high dose of stem cells that are well-matched to the patient, and it has the potential to allow more patients to have a better chance for a successful stem cell transplant.